Drugs / [99mTc]Tc-ZHER2:4107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07292571 | Oct 2025 → Mar 2026 overdue | breast cancer | Tomsk National Research Medical Center of the Russian Academy of Sciences | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [99mTc]Tc-ZHER2:4107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07292571 ↗ |
| Modality | Diagnostic / imaging agent | “SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody” NCT07292571 ↗ |